Frank Morich joins Innate Pharma's board of Directors
Innate Pharma obtains ISO9001:2000 certification for its research and development activities in the field of immunotherapy
Innate Pharma announces the achievement of the first milestone in its collaboration with Novo Nordisk A/S
Innate Pharma welcomes Dr. Squiban as Chief Medical Officer
Financial calendar for 2008 and update on next meetings with analysts and investors
IPH 2201, a novel monoclonal antibody targeting NK cells, enters into regulatory pre-clinical development
Turnover of 5.1 million euros for the first nine months of 2007
Approval from the French authorities to start an exploratory Phase II clinical trial in CML with IPH 1101
Financial results for the first semester of 2007
Number of shares and voting rights, as of July 31, 2007
